A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor
Bone Marrow Transplantation2011Vol. 47(4), pp. 483–487
Citations Over TimeTop 10% of 2011 papers
Sunil Abhyankar, Shaun DeJarnette, Omar S. Aljitawi, Siddhartha Ganguly, Dean Merkel, Joseph P. McGuirk
Related Papers
- → Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone(2010)20 cited
- → The current status in hematopoietic stem cell mobilization(2015)13 cited
- → On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone(2023)1 cited
- → Pegfilgrastim and Planned Plerixafor for Autologous Stem Cell Mobilization Is Safer Than and As Effective As Chemo-Mobilization in Patients with Hematological Malignancies(2015)
- → Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide Mobilization Vs. G-CSF ± Plerixafor Mobilization in the Lenalidomide Era(2021)